HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for ...
Zura Bio Limited (NASDAQ:ZURA – Free Report) – Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Zura Bio in a note issued to investors on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback